BGM BGM Group Ltd.
Listings ·
Class A shares outstanding will fall from 380,623,358 to 12,687,445 when the 30-for-1 consolidation takes effect on October 1, 2026. Shareholders approved it on September 5, 2026, and authorised share capital rises to US$15,090,000.
BGM Group filed the annual report for the year ended September 30, 2025 on July 21, 2026, and Nasdaq said the filing cured the lapse on July 24. The same report shows a net loss of $19.9 million, up from $1.4 million.
BGM Group sold 200,000,000 Class A ordinary shares at US$0.06 each, with warrants for up to another 200,000,000 shares, for gross proceeds of US$12,000,000. The private placement closed on June 8, 2026.
BGM Group Ltd. says it cannot file its annual report on Form 20-F for the year ended September 30, 2025 on time. It is still finishing the consolidation and acquisition accounting for its purchase of YX Management Company Limited.
BGM Group Ltd., formerly Qilian International Holding Group Limited, is a Cayman Islands company. Its PRC business is conducted through a variable interest entity, Gansu Qilianshan Pharmaceutical Co. Ltd. (Gansu QLS), under contractual arrangements. The filing defines the products the group works with. These include Ahan Antibacterial Paste, a disinfection paste made from a mixture of 11 traditional Chinese herbal ingredients used to treat refractory chronic skin diseases, and Gan Di Xin, an innovative antitussive and expectorant medicine made from raw licorice materials. Other defined products include Qilian Shan licorice extract, Qilian Shan oxytetracycline APIs, and a heparin sodium preparation, which is a primary ingredient for pharmaceutical companies producing medications for cardiovascular diseases, cerebrovascular diseases and hemodialysis. The filing also defines Xiongguan Organic Fertilizer and Zhu Xiaochang Sausage Casings, an all-natural food product. Its subsidiaries include Chengdu Qilianshan Biotechnology Co., Ltd., which is 79.71% owned by Gansu QLS, and Moshangfa (Gansu) Fertilizer Industry Co., Ltd.
| Product or program | What it is | Stage |
|---|---|---|
| Ahan Antibacterial Paste | Disinfection paste from 11 traditional Chinese herbal ingredients for chronic skin diseases | |
| Gan Di Xin | Antitussive and expectorant medicine made from raw licorice materials | |
| Heparin Sodium Preparation | Primary ingredient for medications for cardiovascular and cerebrovascular diseases and hemodialysis | |
| Qilian Shan Licorice Extract | Primary ingredient for manufacturing traditional licorice tablets | |
| Qilian Shan Oxytetracycline APIs | Active ingredient for medications using oxytetracycline | |
| Xiongguan Organic Fertilizer | Fertilizer product designed to improve crop yield |
| Line | FY ended Sep 30, 2025 | FY ended Sep 30, 2024 |
|---|---|---|
| Revenue | $37.9 million | $25.1 million |
| Research and development | $672,669 | $1.4 million |
| Net income (loss) | -$19.9 million | -$1.4 million |
| Cash from operations | -$2.4 million | $544,238 |
| Cash and equivalents | $9.8 million | $9.8 million |
Our latest story on this, dated Jun 9, 2026: "BGM Group closes US$12,000,000 private placement of 200,000,000 shares and warrants". The story links the filing or release it is based on. Read the story.
BGM Group Ltd. trades under the ticker BGM on NASDAQ.
BGM Group Ltd. is listed on NASDAQ.
The SEC Central Index Key (CIK) for BGM Group Ltd. is 1779578. Its filings are on SEC EDGAR.
35,750,000 shares as of 2023-09-30, per the cover page of its 20-F filed 2024-02-15.
Our directory records BGM Group Ltd. under China.
Our directory classifies BGM Group Ltd. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for BGM Group Ltd. is KYG7307E1310.
aibio.space lists BGM Group Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as E9.
BGM Group Ltd., formerly Qilian International Holding Group Limited, is a Cayman Islands company. Its PRC business is conducted through a variable interest entity, Gansu Qilianshan Pharmaceutical Co. Ltd. (Gansu QLS), under contractual arrangements.
Ahan Antibacterial Paste: Disinfection paste from 11 traditional Chinese herbal ingredients for chronic skin diseases
Gan Di Xin: Antitussive and expectorant medicine made from raw licorice materials
$37.9 million for the fiscal year ended Sep 30, 2025, as reported to the SEC.
BGM Group Ltd. reported a net loss of $19.9 million for the fiscal year ended Sep 30, 2025, and used $2.4 million of cash in operations, per its annual report to the SEC.
Reported a reverse stock split. SEC Form 6-K. Source
Reported a reverse stock split. SEC Form 6-K. Source
Reported a reverse stock split. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a reverse stock split. SEC Form 6-K. Source
Reported a reverse stock split. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Told the SEC a periodic report would be filed late. SEC Form NT 20-F. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio